SECOND AND THIRD-GENERATION HEPATITIS B VACCINES

费用、可获得性和/或未完全接受基于无根据的 害怕感染艾滋病的病原体限制了影响 发达国家和发展中国家的血浆衍生乙肝疫苗。 因此，需要新的疫苗开发方法。 重组DNA和合成肽技术似乎提供了最好的 为下一代乙肝疫苗提供机会。部分或 已经证明了对乙肝的完全保护作用 (A)重组衍生亚单位免疫后的黑猩猩 (B)活的重组牛痘病毒 含有乙肝病毒基因；和(C)代表乙肝表面抗原的合成肽 序列。尝试确定最重要的抗原域 刺激性中和抗体目前正在进行中。

Expense, availability and/or incomplete acceptance based upon an unfounded fear of infection with the agents of AIDS limit the impact of plasma-derived hepatitis B vaccines in developed and developing countries. There is therefore a need for new approaches to vaccine development. Recombinant DNA and synthetic peptide technologies appear to offer the best opportunities for the next generation of hepatitis B vaccines. Partial or complete protection against hepatitis B has been demonstrated in chimpanzees following vaccination with (a) recombinant derived subunit vaccine prepared in eukaryotic cells, (b) live recombinant vaccinia virus containing HBV genes, and (c) synthetic peptides representing HBsAg sequences. Attempts to identify the antigenic domains most important in stimulating neutralizing antibody are currently in progress.